Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

38.10

+1.17 (3.17%)

as of Aug 25, 2026, 8:00:00 pm Market Open.

70 watching

Investor Insights

Aug 25, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

Teva Pharmaceutical, currently rated TEVA-N, has gained attention due to a recent credit rating upgrade from Moody's, emphasizing the success of its growth strategy bolstered by key innovative products, a robust pipeline, and ongoing debt reduction. Despite some fluctuations in stock performance and concerns regarding the pharmaceutical sector's competitiveness, especially with generics entering the market, Teva's operational metrics are improving, including revenue diversity and solid free cash flow. The leadership under the current CEO has been particularly transformative, seeing a significant turnaround since early 2023. However, experts highlight mixed sentiments about Teva's innovative capabilities, suggesting caution for investors looking for standout pharmaceuticals. Nonetheless, the stock has shown strong accumulation and resilience in a favorable drug market lately.

Consensus

Positive

Valuation

Fair Value

Similar

Pfizer,PFE

PAST TOP PICK

(Top Pick Mar 1/11, Down 9.03%) The stock hasn’t worked out. He bought more at $40. Raised dividend 11 years in a row, made a nice acquisition. He does not know why it is at these levels.

TOP PICK

Likes companies that have low valuations, great history of rising dividends and potential for double digit earnings growth in the coming year. Thinks it will earn $5.50 in 2012. Trading at 8X earnings. Raised its dividends 12 years in a row. Thinks they will be very active looking to acquire big quality branded orphan drugs.

STRONG BUY

Not sure why it has been beaten up so much but may have to do with a recent acquisition and concerns on how they are going to integrate it. 3 of the worst performing stocks this year are financials, pharmaceuticals and technology. Very, very cheap valuation. Raised its dividends 10 years in a row.

SELL

Really likes the generic drug business but he sold it because it is not a pure play generic. They also have the leading MS drug under patent. It will go off patent in the next year or so, so they also have a patent cliff. It is finally getting some real competition in the MS area. He decided to move on.

DON'T BUY

The largest generic drug producer but also have a branded division. There is concern that there will be increasing competition. As well, expect there will be increasing pressure for any industry that is being reimbursed by governments, especially the US. As the market improves, this stock should lift from here but longer-term, she wouldn't be a buyer.

COMMENT

Generic drugs plus one big branded drug that is going to face a lot of competition. Very attractive valuation. Not too excited about their acquisition of Cephalon. Not significantly adding to his holdings at this price. If you think it is going to recover, this is a great price.

STRONG BUY

Generic drug industry – governments should have preference for generic drugs. They will continue to grow. They had patent challenges from an MS drug they make. Should come to court in the fall. Market will eventually realize there is more value. Worth looking at. He was thinking of recommending it as a top pick today.

DON'T BUY

Recently sold his holdings. Liked the generic drug business. This one is not exclusively generic. Their biggest product that contributes the most to earnings is a multiple sclerosis drug and this will be coming off patent in the next couple of years. A lot of competition coming out on this drug.

DON'T BUY

Healthcare in the US had a pretty good run followed by a precipitous drop. There are probably better names.

COMMENT

Making all kinds of generic drugs and also do their own research/development and doing non-generic drugs as well. Not cheap enough for him to buy.

BUY

Generic drugs and its prospects are very strong. A lot of value under $50 a share. Trading at less than 10X earnings. Just made a big acquisition. Doing all the right things.

PAST TOP PICK

(A Top Pick Apr 29/10. Down 13.9%.) Still likes and is still buying. Suffered from headline risk on one of its drugs.

BUY

Lots of exciting news in the last 3 weeks. They have one blockbuster drug for MS. Another competitor came out with good results on the competing new drug. Cephalon is a small acquisition for them, but has 4 strong branded drugs. US Health care stocks have been beaten down too much and there are good entry points on a lot of names. Started buying TEVA about a month ago.

DON'T BUY

Had great growth over the last number of years. The big news was their outbidding Valeant (VRX-T) for Cephalon (CEPH-Q). Didn’t have to pay up much for this. This should keep growth going for them. He is not big on pharmaceuticals and sees no need to chase it at this price.

DON'T BUY

Buying Cephalon (CEPH-Q), which diversifies their revenue source from their branded drugs. Have a very successful branded drug for treating multiple cirrhosis but there is potential competition coming in the next couple of years. Trading at a very low multiple, below 10X. She prefers more diversified health care names.

Showing 151 to 165 of 277 entries

Most Recent Experts

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Teva Pharmaceutical (TEVA)